AyuVis Research

Executive Summary

AyuVis Research is a private, preclinical-stage biopharmaceutical company based in Louisville, US, focused on developing novel small molecule therapeutics for severe respiratory conditions, including bronchopulmonary dysplasia (BPD), pulmonary alveolar proteinosis (PAP), and acute respiratory distress syndrome (ARDS) induced by SARS-CoV-2 and other coronaviruses. The company's platform aims to address the underlying pathology of complicated respiratory infections with promising preclinical data. The unmet need is significant, especially for ARDS, which has limited treatment options. AyuVis's approach could offer a new class of drugs to modulate the inflammatory and fibrotic processes. At the preclinical stage, the company faces typical development risks, including funding and regulatory hurdles. However, if successful, it could capture a substantial market in respiratory disease.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Lead ARDS Candidate30% success
• Q2 2026Pivotal Preclinical Efficacy Data Readout50% success
• Q4 2026Series A Financing Announcement40% success